A novel dual luciferase assay for the simultaneous monitoring of HIV infection and cell viability

Journal of Virological Methods
Yu-Ya MitsukiYasuko Tsunetsugu-Yokota

Abstract

Human immunodeficiency virus type 1 (HIV-1) reporter cell lines are critical tools for drug development. However, one disadvantage of HIV-1 reporter cell lines is that reductions in reporter gene activity need to be normalized to cytotoxicity, i.e., live cell numbers. Here, we developed a dual luciferase assay based on a R. reniformis luciferase (hRLuc)-expressing R5-type HIV-1 (NLAD8-hRLuc) and a CEM cell line expressing CCR5 and firefly luciferase (R5CEM-FiLuc). The NLAD8-hRLuc reporter virus was replication competent in peripheral blood mononuclear cells. The level of hRLuc was correlated with p24 antigen levels (p<0.001, R=0.862). The target cell line, R5CEM-FiLuc, stably expressed the firefly luciferase (FiLuc) reporter gene and allowed the simultaneous monitoring of compound cytotoxicity. The dual reporter assay combining a NLAD8-hRLuc virus with R5CEM-FiLuc cells permitted the accurate determination of drug susceptibility for entry, reverse transcriptase, integrase, and protease inhibitors at different multiplicities of infection. This dual reporter assay provides a rapid and direct method for the simultaneous monitoring of HIV infection and cell viability.

References

Jul 21, 1999·Proceedings of the National Academy of Sciences of the United States of America·K YoshimuraH Mitsuya
Jun 3, 2006·The Journal of Infectious Diseases·Rochelle P WalenskyKenneth A Freedberg
Mar 7, 2009·Science·Douglas D RichmanRoger J Pomerantz
Jan 6, 2010·Current Opinion in HIV and AIDS·Christina Ochsenbauer, John C Kappes
Jun 2, 2011·Annals of Internal Medicine·Carl W Dieffenbach, Anthony S Fauci
Jun 4, 2011·Nature Protocols·Dirk DaelemansChristophe Pannecouque
Dec 3, 2013·Journal of Immunological Methods·Marloes A NaardingJill Gilmour
Mar 13, 2014·Journal of Immunological Methods·Marcella Sarzotti-KelsoeDavid C Montefiori

❮ Previous
Next ❯

Citations

May 1, 2020·Cytometry. Part B, Clinical Cytometry·Elena MaryamchikMarcela V Maus

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.